HIV-1 cure has been reported in two men with HIV-1 and malignancy following CCR5δ32 homozygous allogeneic adult stem cell transplantation. Prof. Yvonne Bryson (David Geffen School of Medicine, UCLA, and UCLA Mattel Children’s Hospital, Los Angeles, CA, USA) reports on a woman in ART-free HIV-1 remission for 14 months following CCR5∆32 homozygous cord blood and CD34-selected haploidentical stem cell transplant (haplo-cord SCT) for acute myeloid leukaemia.
The abstract entitled: ‘HIV-1 Remission with CCR5δ32δ32 Haplo-Cord Transplant in A US Woman: IMPAACT P1107’ (Abstract #65) was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- Could you give us a brief overview of the case of the woman who has achieved HIV remission after stem cell transplant? (0:09)
- What are the aims and design of the IMPAACT P1107 study? (1:43)
- What other study findings have been observed to date? (3:16)
- What are the implications of this case on HIV therapy? (4:08)
- What questions remain unanswered and what further research is planned? (5:17)
Disclosures: Prof. Yvonne Bryson has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022
Share this Video
Related Videos In HIV
Moti Ramgopal, IDWeek 2022: Unmet needs and challenges around maintenance of HIV-1 virologic suppression
In this touchINFECTIOUS DISEASES interview, we met with Dr Moti Ramgopal (Midway Research Center, FL, USA) to discuss the unmet needs and challenges around maintenance of HIV-1 virologic suppression. Dr Ramgopal discusses challenges around stigma, social issues, tolerability, injection site reactions, and patient satisfaction with their current treatment regimen. Access an interview with Dr Moti […]
Moti Ramgopal, IDWeek 2022: Phase 3/3b FLAIR and ATLAS-2M pooled analysis – Efficacy and safety outcomes through week 96 by race
Long-acting cabotegravir + rilpivirine administered monthly or every 2 months is the first and only complete long-acting regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. In this touchINFECTIOUS DISEASES interview, we met with Prof. Moti Ramgopal (Midway Research Center, FL, USA) to discuss a post hoc analysis of pooled outcomes for […]
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!